(UroToday.com) In this discussion, Dr. Perner elaborated on the various molecular subtypes of prostate cancer. It has been shown that there are potentially actionable mutations in 25% of cases in the PIK3CA/MAPK signaling pathway and almost 20% alteration in DNA damage repair genes (Figure 1).